14 publications
| Name | Date | Type | Actions |
|---|---|---|---|
SALES 1st quarter 2024: €134M The Vetoquinol Group recorded sales of €133.7 million in the 1st quarter of fiscal 2024, including €83.4 million for Essential products. |
29/04/2024 | Public releases | |
Availability of the 2023 universal registration document On 24 April 2024, Vetoquinol filed its 2022 Universal Registration Document with the Autorité des Marchés Financiers (AMF) in ESEF (European Single Electronic Format). |
24/04/2024 | Public releases | |
2023 ANNUAL RESULTS Annual sales: €529m (stable at constant exchange rates) |
20/03/2024 | Public releases | |
Annual sales 2023: €529 million Annual Sales of Essential products: €313 million (up 4.5% at constant exchange rates) |
24/01/2024 | Public releases | |
Third quarter revenues: €132 million |
14/10/2021 | Public releases | |
2021 first half results 2021 Half year results |
29/07/2021 | Public releases | |
Availability of the 2020 universal registration document Vetoquinol informs that it has filed its 2020 Universal Registration Document with the Autorité des Marchés Financiers (AMF) on April 28th, 2021. |
28/04/2021 | Public releases | |
Q1 2021 sales Q1 2021 sales : €128M (up 28% at constant exchange rates, up 24% as reported)
Q1 2021 essential sales : €72.6M (up 38% at constant exchange rates, up 36% as reported)
|
15/04/2021 | Public releases | |
2020 annual results 2020 sales: €427.5m (up 8.0% as reported)
EBIT before depreciation of assets arising from acquisitions: €65.3m (up 33.5%)
Net income - Group share: €19.2m (4.5% of sales)
Cash flow: €92.2m
|
01/04/2021 | Public releases | |
Vetoquinol wins the Animal Pharm’s award for best European company 2020 February 8th, 2021 (Lure, France) - Vetoquinol announced today it has been awarded “Best European Company 2020” by Animal Pharm. |
08/02/2021 | Public releases | |
Vetoquinol acquires the rights for Profender® from Elanco Animal Health for Canada February 8th, 2021 (Lure, France) - Vetoquinol announced today the acquisition of the Canadian rights to Profender® product family from Elanco Animal Health. |
08/02/2021 | press release excluding results | |
2020 sales: €427.5M (up 8.0% as reported, up 10.9% at constant exchange rate) essentials sales: €220.6M (up 15.7% as reported, up 17.3% at constant exchange rate) Vetoquinol CEO Matthieu Frechin said: “2020 was an exceptional year on a number of counts. Above all, it is important to pay tribute to our teams, whose hard work and exemplary dedication allowed us to manage the impact of the health crisis. Year on year, we achieved double-digit sales growth at constant exchange rates, driven by our Essentials products. This momentum accounts for additional sales of €43 million (at constant exchange rates). We also completed a major acquisition in the form of the Drontal® and Profender® product ranges, entailing three structural effects for Vetoquinol: a scale effect, a product mix effect in the Essentials range and potential extensions, the first of which has been confirmed in January 2021 for the Australian market. We are optimistic for our business outlook in 2021, while being vigilant in relation to the global sanitary situation.” |
21/01/2021 | Public releases | |
Orion Animal Health and Vetoquinol expand collaboration - Vetoquinol to distribute Orion’s Clevor® in the USA and Orion to distribute Drontal® and Profender® products in Finland, Hungary and Romania Orion Animal Health and Vetoquinol are expanding their collaboration with new distribution agreements. |
18/01/2021 | Public releases | |
Vetoquinol acquires the rights for Drontal® and Profender® families from Elanco animal health for Australia January 11th, 2021 (Lure, France) - Vetoquinol announced today the acquisition of the Australian rights to Drontal® and Profender® product families from Elanco Animal Health. |
11/01/2021 | Public releases |